We read with interest the PNAS article by Schmid et al. entitled "Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11β-hydroxysteroid dehydrogenase" (11β-HSD) (1) . Although we welcome most of the findings and interpretation, several points raised our concern. i) After analyzing the enlarged digital versions of Fig. 5 A and B, we do not agree with the authors' conclusion that INS-1 cells had positive expression of 11β-HSD1 mRNA and protein; there was hardly any detectable protein/mRNA band in the Western blot and RT-PCR gel image. More troubling evidence was from Fig. 6A vs. Fig. 6B showing an approximately 27-fold higher level of 11β-HSD2 vs. -HSD1, adding to our doubt whether 11β-HSD1 was expressed in these cells. We therefore disagree with the following italicized phrases in their Results (1) HSD1 staining in most islet cells or at least many β-cells, and in cell nuclei, if one compares them with the cytosolic staining of insulin on the right panels. They contradict current consensus that 11β-HSD1 is expressed by α-and PP-rather than β-cells of the pancreas and mostly in microsome (cytosol), which should not have been ignored by the authors (2) . In fact, we have observed similar nonspecific staining, as extensive as that of insulin, when using presumably the same anti-11β-HSD1 antibody marketed by Abcam (cat. no. ab39364). By contrast, the anti-11β-HSD1 antibody procured from Santa Cruz Biotechnology (cat. no. sz20175) provided more specific, α-cell-specific signal in our study.* Therefore, we believe that the authors' statement (1) that, "In addition, the 11β-HSD-1 protein was detected by immunohistochemical staining in human pancreatic islets [ Fig. 5C ], rat pancreatic islets [ Fig. 5D ], and INS-1 cells [ Fig. 5E ]" is misleading and inaccurate.
iii) To measure 11β-HSD enzyme activity, enzyme immunoassay was used, as in the supplemental data. We believe the current standard is to use radiolabeled substrates ([   3   H ]dehydrocorticosterone) and separate it from the conversion product (corticosterone) using TLC followed by scintillation counting of radioactivity on the corresponding bands (2, 3) . We thus doubt the specificity and sensitivity of the assay result in Fig.  6C . For instance, concerning the assay sensitivity, the result difference was 240 vs. 300 pg/mL, whereas the detection limit is at 57 pg/mL (cat. no. ADI-900-071; Enzo Life Sciences) (1) . If so, especially if INS-1 cells hardly express 11β-HSD1, the result contained in Fig. 6C may not, in our opinion, be accurate.
Thus, we have reservations on the interpretation of Figs. 5 and 6 and the findings concerning 11β-HSD1. Specifically, we disagree with the authors' conclusion that 11β-HSD1 was expressed in normal β-cells and INS-1 cells based on Fig. 5 (1) . If 11β-HSD1 was not supposed to be expressed in INS-1 cells, especially if a nonconventional enzyme assay has been used, the result of Fig. 6C showing corticotropin-releasing hormone-induced inhibition also becomes questionable. 
